Acurx Pharmaceuticals (ACXP) Q3 2026 earnings review
Acurx starts its small antibiotic trial, but cash burn rises
Acurx Pharmaceuticals, a developer of antibiotics for severe gut infections, started its small human study while its cash reserves shrank. The pre-revenue biotech enrolled the first patient in its 20-person trial for recurring infections at the end of September, which pushed quarterly operating costs up 30% to $2.6 million. Even after raising $1.5 million by selling new stock, cash dropped by $1 million to $9.7 million.
| Ending cash | $9.7M down from $10.7M last quarter |
|---|---|
| Operating expenses | $2.6M +30% from a year ago |
| Shares outstanding | 5.88M +26% in a single quarter |
| Phase 3 acute-CDI plan | Unchanged still waiting for financing |
⚖️ Verdict: 🔴 Bearish
The story got worse because clinical spending now outpaces stock sales, while the main Phase 3 trial remains unfunded. Share count jumped 26% in a single quarter and more than tripled from a year ago, yet cash still fell and the FDA gave no up-front promise that a single Phase 3 trial will be enough. On the plus side, the funded 20-patient pilot is now underway and could open a smaller regulatory path if it works.
The question now is whether the 20-patient trial can produce convincing data before Acurx exhausts its remaining credit line and cash. Either the pilot data attracts a partner to fund a pivotal study, or the company faces another dilutive financing to keep operating. Enrollment updates and cash burn over the next two quarters will tell.
🐂 Bull Case
The Small Recurrent-Infection Trial Started Enrolling
Acurx develops ibezapolstat, an oral antibiotic for Clostridioides difficile infection (CDI), a severe gut infection. Because the drug developer lacks the money to start its large Phase 3 trial in first-time infections, its near-term progress rests on a smaller study. On September 29, the company "began enrolling patients in PATHFINDER, a ground-breaking 20 patient clinical trial in multiply-recurrent CDI" for patients whose infection keeps coming back.
The company said PATHFINDER is fully funded. It also outlined a backup plan: if the 20-patient study succeeds, "we may have the flexibility to conduct a pivotal Phase 3 trial (PATHFINDER II) in recurrent CDI under the FDA's LPAD Pathway instead of conducting the ASPIRE trial in acute CDI to gain approval." LPAD is a regulatory program for antibacterial drugs that treat small, high-need patient groups, which allows smaller registration trials.
What to watch: how many of the 20 patients Acurx has enrolled when it reports fourth-quarter results. Fast enrollment would bring clinical data in 2027, while slow recruiting would burn cash before any readout arrives.
New Patents and Lab Studies Back the Drug Class
Acurx wants to prove its drugs kill harmful bacteria without wiping out helpful gut microbes, which makes infections less likely to return. In October, a journal of the American Society for Microbiology published data comparing Acurx's preclinical antibiotics with linezolid, an existing antibiotic, in mice. The study showed Acurx's compounds lowered bacterial levels while sparing healthy gut function.
The drug maker also renewed its research partnership with Leiden University Medical Center to map the "first-ever 3D structure of Pol C from methicillin-resistant Staphylococcus aureus (MRSA) in complex with an Acurx inhibitor". Patent offices in Japan and Mexico granted new patents running through June 2042. These steps strengthen the scientific package for prospective partners, though preclinical papers do not fund human trials.
What to watch: whether these scientific publications lead to a licensing deal or research grant in the next two quarters. A funded partnership would validate the platform and ease the cash crunch.
🐻 Bear Case
Cash Burn Topped Stock Sales This Quarter
After four straight quarters of raising more money than it spent, Acurx saw its cash balance fall in the third quarter. Starting the PATHFINDER trial pushed research and development spending up 160% from a year ago to $1.1 million, "as a result of costs associated with the new recurrent CDI trial program", the company said. Last year's third quarter was a low point for spending while trials paused.
- Ending cash: $9.7 million, down from $10.7 million in the second quarter
- Total operating expenses: $2.6 million, up 30% from a year ago and 14% from last quarter by our math
- Implied cash used before financing: about $2.5 million by our math, after counting $1.5 million raised from stock sales
- Remaining equity credit line: about $2.6 million by our math from the $12 million facility
At the third-quarter spending pace, ending cash covers about 3.7 quarters of operations by our math. The quarterly filing, which is not yet included in these materials, carries the updated going-concern note, Nasdaq listing details, and any stock sales made after September.
What to watch: the cash flow statement and subsequent-events footnote in the third-quarter 10-Q filing. They will show how much of the remaining credit line Acurx has already tapped since September 30.
Share Sales Tripled the Share Count in One Year
The earnings release shows diluted net loss per share narrowing to $0.49 from $1.23 a year ago. In fact, the actual net loss got worse, rising 30% by our math from $2.0 million to $2.6 million. The per-share loss shrank only because Acurx divided a larger loss across more than three times as many shares.
To fund its operations and the PATHFINDER start-up, the company raised $1.5 million during the quarter through its equity line of credit, an arrangement that lets it sell new stock into the market. By our math, Acurx issued 1.2 million net new shares during the third quarter alone. Total shares outstanding reached 5.88 million on September 30, up 26% from June and up 227% from 1.80 million a year earlier. Because the company has no revenue and a shrinking equity line, ongoing operations require further share issuance unless a partner steps in.
What to watch: the share count on the cover of the upcoming 10-Q filing. A jump above the 5.88 million September figure would show heavy fourth-quarter stock sales.
The Main Phase 3 Trial Still Lacks Funding
Earlier this year, Acurx highlighted an FDA policy shift toward allowing a single Phase 3 trial as the default for drug approval, instead of two. In July, the company met with the agency to ask if one Phase 3 trial in acute CDI, called IBZ-ASPIRE, would be enough to file for approval. The FDA did not commit up front.
Instead, the agency stated it is "open to further discussion on the totality of evidence from the ibezapolstat clinical development program at a pre-NDA meeting after completion of a single Phase 3 trial" alongside PATHFINDER data. Meanwhile, starting IBZ-ASPIRE remains "subject to obtaining appropriate financing", the same condition attached to the study for the past two years. Without a partner or major financing, the primary acute-CDI program remains on hold.
What to watch: whether management drops IBZ-ASPIRE in favor of the smaller LPAD recurrent-CDI path. That shift would admit that funding for the main acute-CDI market is out of reach.
👓 Other Themes
Regulators Cleared the Brand Name CIFBEZY
In August 2026, Acurx received conditional acceptance from the FDA and a trademark allowance from the US Patent and Trademark Office for CIFBEZY, the planned commercial brand name for ibezapolstat. The clearance checks off a routine regulatory box ahead of future registration filings, though commercial launch still depends on completing Phase 3 trials and winning final drug approval.
💲 Other KPIs
Prepaid expenses — advance payments for future clinical and administrative services — nearly tripled from $233,084 in the second quarter and rose more than sevenfold from $85,018 at the end of 2025. The jump reflects upfront site and vendor payments as the 20-patient PATHFINDER trial began enrolling at the end of September.
Unpaid bills and accrued expenses — the company's only liabilities, as it carries no debt — rose 5.7% from $2.83 million in the second quarter and 23.6% from $2.42 million at year-end by our math. Payables now equal 31% of the company's ending cash balance, leaving $7.3 million in net working capital.
Overhead spending fell 5.2% from $1.60 million a year ago on lower legal and professional fees, but climbed 22.6% from $1.24 million in the second quarter by our math. For the first nine months of 2026, overhead costs totaled $4.13 million, down from $4.92 million in the same period last year.
🔮 Guidance
Unchanged. The antibiotic developer still says its main Phase 3 acute-CDI trial is ready to advance once it secures financing, the same status it has held for over a year. The release added that if the 20-patient PATHFINDER study succeeds, the firm may run a smaller Phase 3 trial in recurrent infections instead of ASPIRE.
❓ Key Questions
How much capacity remains on the equity credit line?
Acurx drew $1.5 million from its $12 million equity line in the third quarter, leaving about $2.6 million by our math. Because the 10-Q filing is not yet included, investors need to know how much capacity remains after October and November sales.
When will the 20-patient PATHFINDER trial finish enrolling?
The company enrolled its first patient on September 29 after slipping from an earlier August target. Because multiply-recurrent CDI patients are harder to find, the enrollment pace determines when clinical data will arrive and how much cash the study will consume.
What would the backup PATHFINDER II trial cost?
Acurx said for the first time in a release that it might run a Phase 3 recurrent-CDI trial under the LPAD pathway "instead of conducting the ASPIRE trial". Management has not stated the budget or patient count for that alternative study.
What did the FDA require for a single-trial filing?
The FDA said it is open to discussing the totality of evidence at a pre-NDA meeting after one Phase 3 trial. Management has not disclosed what efficacy hurdle or safety database size the agency asked for in the July meeting minutes.